Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain.

This study shows that the clinical and biologic characteristics of adult patients with BL and BLL were similar to those of patients from the BL-IPI cohort. Consequently, the BL-IPI was validated in our series of patients with BL and BLL. Keywords: Burkitt lymphoma; prognosis; International Prognostic Index; validation EN Burkitt lymphoma prognosis International Prognostic Index validation 1993 1996 4 08/22/22 20220801 NES 220801 Chemoimmunotherapy including rituximab and high-dose or infusional chemotherapy constitute the standard treatment for patients with Burkitt's lymphoma (BL) or Burkitt's lymphoma and leukemia (BLL) [[1], [3]]. [Extracted from the article]